Eli Lilly (NY:LLY)

1,142.85 -7.00 (-0.61%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016 ↗

September 21, 2026

The top healthcare stock has been underperforming the market, and its returns haven't been as impressive as in recent years.

Via The Motley Fool

Meet the Vanguard ETF That Increased Its SpaceX Holding by 39% in 1 Month and Shows No Signs of Slowing Down ↗

September 20, 2026

The unlocking of SpaceX shares is reshaping the communications sector.

Via The Motley Fool

Topics ETFs

Eli Lilly (NYSE:LLY) Fits a Dividend Quality Screen Despite Its Low Yield ↗

September 18, 2026

Via Chartmill

Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup ↗

September 11, 2026

Via Chartmill

Why Twist Bioscience Stock Skyrocketed This Week ↗

September 18, 2026

It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.

Via The Motley Fool

Topics Artificial Intelligence

Better Buy for Cautious Investors: Eli Lilly vs Costco ↗

September 18, 2026

These companies may perform well in any market environment.

Via The Motley Fool

Topics Artificial Intelligence Economy

Automated Labeling Tools Are Modernizing the AI Training Dataset Market ↗

September 18, 2026

The global AI training dataset market was valued at USD 3.2 billion in 2025 and is projected to reach USD 16.3 billion by 2033, expanding from USD 3.9 bill

Via Talk Markets

Topics Artificial Intelligence

1 Safe-and-Steady Stock Worth Your Attention and 2 We Question

September 18, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Ch...

Via StockStory

Topics Emissions

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗

September 17, 2026

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Via The Motley Fool

This Trend is Excellent News for Eli Lilly and Its Investors ↗

September 17, 2026

Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.

Via The Motley Fool

Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure? ↗

September 16, 2026

FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.

Via The Motley Fool

Topics ETFs

5 Buy-and-Hold Stocks Built to Weather a Volatile Market ↗

September 16, 2026

Ahead of Q4 2026, analysts favor Western Digital, NVIDIA, Vertiv, Eli Lilly, and JPMorgan Chase as steady, best-in-class stocks offering growth with less volatility for buy-and-hold investors.

Via MarketBeat

Topics Artificial Intelligence

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗

September 16, 2026

The company is still looking to bounce back after the beating it took in recent years.

Via The Motley Fool

Topics Economy

VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗

September 15, 2026

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

Via The Motley Fool

Topics ETFs

Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗

September 15, 2026

The drugmaker has a lot riding on continued clinical progress.

Via The Motley Fool

3 Healthcare Stocks for 3 Stages of Life ↗

September 15, 2026

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.

Via MarketBeat

3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗

September 15, 2026

These stocks have been struggling lately, but they could be underrated buys in the long run.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets ↗

September 14, 2026

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing...

Via MarketBeat

This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy? ↗

September 14, 2026

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

Via The Motley Fool

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗

September 14, 2026

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Via The Motley Fool

State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors ↗

September 13, 2026

XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost.

Via The Motley Fool

Topics ETFs

Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst ↗

September 13, 2026

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

Via The Motley Fool

IXJ vs XPH: Global Healthcare ETF or Pharma Focus? ↗

September 11, 2026

XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.

Via The Motley Fool

Topics ETFs

Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗

September 11, 2026

The worst may be in the rearview mirror for the drugmaker.

Via The Motley Fool

Amgen Drops 10% on a Trial It Didn't Even Run ↗

September 11, 2026

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Via MarketBeat

Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report ↗

September 11, 2026

Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.

Via Benzinga

These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy. ↗

September 10, 2026

During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average.

Via The Motley Fool

Topics ETFs Economy

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH ↗

September 10, 2026

Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.

Via The Motley Fool

Topics ETFs

VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials

September 10, 2026

Via AB Newswire

Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? ↗

September 10, 2026

One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.